NVO Novo Nordisk A/S
Company Analysis
Latest News
🔴 Novo Nordisk falls 4.7% as Q2 results show mixed performance and impairment charges
• Novo Nordisk is trading 4.7% down today at $44.88 following the release of its Q2 2026 financial results and updated outlook today, August 4, 2026. • While...
Novo Nordisk A/S Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
For the second quarter of 2026, analysts expect Novo Nordisk to report consensus revenue of $11.27 billion and EPS of $0.82, with the current stock price of...
🔴 Novo Nordisk is trading 9.3% down today after experimental drug Ziltivekimab failed key cardiovascular trial
Novo Nordisk is trading 9.3% down at $46.82 due to significant company-specific news impacting its pipeline and legal standing: • The company announced that...
🔴 Novo Nordisk is trading 10.5% down today on U.S. obesity-drug slowdown and pricing pressure
Novo Nordisk is trading 10.5% down at $46.19 after signaling that its U.S. obesity-drug business is decelerating faster than investors expected ahead of its Q2...
Novo Nordisk Crashes 9% Before Q2 Print — Can the Wegovy Pill Outrun a Price Squeeze That Keeps Getting Worse?
Shares tumbled to $46.83 in pre-market trading, erasing a week of gains in a single session as Novo Nordisk signaled that its U.S. obesity-drug business is...
🔴 Novo Nordisk is trading 9.3% down today after ZEUS trial fails to meet primary endpoint
• Novo Nordisk is trading at $46.83 (-9.26%) in pre-market after announcing headline results from its ZEUS cardiovascular outcomes Phase 3 trial. • The trial...
Novo Nordisk faces fraud lawsuit, allegedly hid CagriSema trial protocols
A U.S. federal judge ruled Novo Nordisk must face a shareholder class-action lawsuit alleging securities fraud. The lawsuit, filed in the District of New...
🟢 Novo Nordisk is trading 3.1% up today on sector rally and defensive rotation
Novo Nordisk is trading 3.1% up at $51.19 as shares benefit from a broader healthcare sector rally and a rotation away from technology stocks. • The stock is...
Novo Nordisk Debuts World-First Weekly Diabetes Injection in China
Novo Nordisk and Fangzhou Inc. launched the diabetes treatment Kyinsu® in China. This release marks the product's global commercial debut. Kyinsu® is the...
Novo Nordisk launches cheaper Ozempic copy, targeting South Africa's grey market
Novo Nordisk will launch Extensior in South Africa on July 27. Extensior serves as a more affordable, authorized copy of the blockbuster diabetes drug...
🟢 Novo Nordisk is trading 3% up today as it rebounds from recent GLP-1 pricing concerns
Novo Nordisk is trading 3% up at $50.55, rebounding from recent weakness tied to GLP-1 pricing and reimbursement worries. • The move comes despite a warning...
Novo Nordisk launches Awiqli in India, world’s first weekly insulin
Danish pharmaceutical company Novo Nordisk launched Awiqli in India on Thursday. Awiqli is the world’s first once-weekly basal insulin approved for clinical...
Novo and Lilly face Medicare limits, restricted to heart disease patients
Medicare is expanding coverage for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. Federal law prohibits Medicare Part D from covering drugs solely for weight...
Novo Nordisk's Wegovy wins UK approval, targeting MASH liver disease
The UK Medicines and Healthcare products Regulatory Agency (MHRA) approved Novo Nordisk's Wegovy (semaglutide injection) for metabolic-associated...
🟢 NVO is trading 3.1% up today after Medicare launches GLP-1 Bridge program for Wegovy
NVO is trading 3.1% up now at $50.30 after Medicare officially launched its GLP-1 Bridge program for obesity drug Wegovy, expanding coverage with a $50 monthly...
🟢 NVO is trading 3.2% up today as Medicare launches GLP-1 Bridge program for Wegovy
NVO is trading 3.2% up at $49.48 as Medicare’s GLP-1 Bridge program officially launches, significantly expanding insurance coverage for Novo Nordisk’s obesity...
Medicare Opens Its Wallet for Wegovy Tomorrow — Can Volume Overcome Novo Nordisk's Pricing Squeeze?
Shares edged higher as Novo Nordisk prepares for what may be the most consequential shift in its U.S. commercial landscape in years: millions of Medicare...
Novo Nordisk gains as Medicare covers Wegovy, launching $50 co-pay pilot
The U.S. Centers for Medicare & Medicaid Services (CMS) will launch the Medicare GLP-1 Bridge pilot program on July 1, 2026. This initiative marks the first...
Novo Nordisk's U.S. Chief Aims for More Insurance Coverage for Wegovy
Novo Nordisk's top U.S. executive, Jamey Millar, aims to increase the portion of Wegovy sales covered by health insurance. Out-of-pocket purchases currently...
Novo Nordisk Wins a Court Battle Over Copycat Drugs in South Africa — But Can Legal Victories Alone Reverse a Stock in Freefall?
Shares surged as Novo Nordisk scored a rare win in its fight to protect its weight-loss empire. South Africa's High Court granted an interim order blocking...